Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Clinical trial NCT00179725 · TERMINATED
Trial details
- NCT number
- NCT00179725
- Sponsor
- Celgene Corporation
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2005-11-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.